# To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients

> **NCT01023685** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 24 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** CAD106

## Key facts

- **NCT ID:** NCT01023685
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01023685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01023685, "To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01023685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*